Loading
Led LIBRETTO-001 in thyroid cancer, which made selpercatinib the first RET-selective drug approved for RET-driven tumours.
Lori Wirth led the thyroid cancer cohorts of LIBRETTO-001, showing selpercatinib produces high, durable response rates in RET-mutant medullary and RET fusion-positive thyroid cancer, and co-led LIBRETTO-531, which showed it beats cabozantinib or vandetanib first line. She also led trials of lenvatinib and immunotherapy in anaplastic and head and neck cancers and directs the head and neck cancer centre at MGH.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tags thyroid, targeted-therapy.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares Selpercatinib, Thyroid cancer, Small-molecule kinase inhibitors.
Shares Selpercatinib, Thyroid cancer, Small-molecule kinase inhibitors.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares LIBRETTO-531, Selpercatinib.
Shares LIBRETTO-531, Selpercatinib, RET, Small-molecule kinase inhibitors.